Latvian biotech Cellbox Labs secures €3.3M funding to scale personalized gut-on-chip models

Cellbox Labs, a Latvian biotech startup, has secured €3.3 million in funding for continued development of its product portfolio. Part of the funding comes from state aid through the Important Project of Common European Interest (IPCEI) in the healthcare sector “Tech4Cure”.

About Cellbox Labs

• Cellbox Labs is a Riga-based startup specializes in developing advanced organ-on-chip models, with a focus on personalized gut-on-chip systems, biosimilar benchmarking, and AI-driven drug discovery. Cellbox Labs platform integrates live data sensors for O₂ and pH, enabling precise monitoring of experiments without extra hardware. 

• It collaborates with partners to create digital twin models for drug absorption, distribution, and response. According to the company, Cellbox Labs` work aligns with regulatory shifts to reduce animal testing and incorporate AI in drug development.

Investment details 

Cellbox Labs informed that part of the funding comes from state aid through the Important Project of Common European Interest (IPCEI) in the healthcare sector “Tech4Cure”.

• The Tech4Cure initiative is an IPCEI project approved by the European Commission, focusing on innovative medical device technologies to advance predictive, preventive, and personalized medicine. 

Cellbox Labs will use funding to scale personalized gut-on-chip models, integrate sensors for live data, enhance biosimilar testing, and develop digital twin models to improve drug testing and human outcome predictions.

Read more: Stargate Hydrogen has raised €42 million grant financing from IPCEI